Hydroxychloroquine (HCQ) therapy decreased immunoglobulin (Ig) levels in patients with Sjögren syndrome (SS) and rheumatoid arthritis (RA) in previous studies. We found no report of Ig levels of women with IgG subclass deficiency (IgGSD) and systemic lupus erythematosus (SLE), SS, or RA treated with HCQ. We retrospectively evaluated IgG, IgG subclass, IgA, and IgM levels and other characteristics of women at IgGSD diagnosis who did and did not take HCQ for SLE, SS, or RA. There were 132 women (48 subnormal IgG1 only, 49 combined subnormal IgG1/IgG3, and 35 subnormal IgG3 only). Mean age was 49 ± 13 years. Twenty-two women with SLE, SS, RA, or combination thereof reported HCQ ≥ 200 mg/day ≥ 6 months. In each IgGSD subtype, median Ig levels of women who took HCQ were not significantly lower than those of women who did not take HCQ. Women with combined subnormal IgG1/IgG3 who took HCQ had greater median IgG2 than women who did not take HCQ (4.89 g/L (range 4.43, 4.94) vs. 2.57 g/L (1.21, 6.44), respectively; p = 0.0123). Regressions on IgG1, IgG2, and IgG3 revealed positive associations with HCQ therapy (p = 0.0043, 0.0037, and 0.0139, respectively). There were no significant Ig associations with age, SLE, SS, or RA as independent variables. HCQ therapy of SLE, SS, or RA in women with IgGSD was not associated with significantly lower IgG, IgG subclass, IgA, or IgM levels. IgG1, IgG2, and IgG3 were positively associated with HCQ therapy, after adjustment for other variables.

在之前的研究中，羟氯喹 (HCQ) 疗法降低了干燥综合征 (SS) 和类风湿关节炎 (RA) 患者的免疫球蛋白 (Ig) 水平。我们没有发现关于接受 HCQ 治疗的 IgG 亚类缺乏症 (IgGSD) 和系统性红斑狼疮 (SLE)、SS 或 RA 女性 Ig 水平的报告。我们回顾性评估了 IgG、IgG 亚类、IgA 和 IgM 水平以及 IgGSD 诊断女性的其他特征，这些女性因 SLE、SS 或 RA 而服用和未服用 HCQ。共有 132 名女性（48 名仅 IgG1 低于正常，49 名 IgG1/IgG3 联合低于正常，35 名仅 IgG3 低于正常）。平均年龄为 49 ± 13 岁。22 名患有 SLE、SS、RA 或其组合的女性报告 HCQ ≥ 200 mg/天 ≥ 6 个月。在每个 IgGSD 亚型中，服用 HCQ 的女性的中位 Ig 水平并不显着低于未服用 HCQ 的女性。p  = 0.0123）。IgG1、IgG2 和 IgG3 的回归显示与 HCQ 治疗呈正相关（分别为p  = 0.0043、0.0037 和 0.0139）。Ig 与作为自变量的年龄、SLE、SS 或 RA 没有显着关联。IgGSD 女性 SLE、SS 或 RA 的 HCQ 治疗与 IgG、IgG 亚类、IgA 或 IgM 水平显着降低无关。调整其他变量后，IgG1、IgG2 和 IgG3 与 HCQ 治疗呈正相关。